[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontitis-stage-3\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontitis-stage-3":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,78,108,136,165,189,212,241,268,309],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652214","morphological-characteristics-of-mandibular-molar-furcation-involvement-and-efficacy-of-regenerative-surgical-treatment-100652214",false,"NCT07770256","Morphological Characteristics of Mandibular Molar Furcation Involvement and Efficacy of Regenerative Surgical Treatment","Morphological Characteristics of Furcation Involvement in Mandibular Molars and Efficacy of Regenerative Surgical Treatment: A Cross-Sectional and Interventional Trial","Inclusion Criteria:\n\n* Patients aged 18 years or older who signed the informed consent form.\n* Diagnosed with Stage III or Stage IV periodontitis according to the 2017 AAP\u002FEFP classification.\n* Completed non-surgical periodontal therapy with full-mouth plaque score (FMPS) and bleeding on probing (FMBS) \\\u003C= 20%.\n* Presence of at least one mandibular molar with Hamp Class II furcation involvement (horizontal bone loss \\> 3 mm without through-and-through communication).\n* Target tooth requirements:\n\n  * Probing pocket depth (PPD) \\>= 5 mm.\n  * Clinical attachment loss (CAL) \\>= 3 mm.\n  * Tooth mobility \\\u003C= Grade I (Miller index).\n  * Vital pulp or adequately filled root canal treatment without periapical radiolucency.\n  * Gingival margin positioned coronal to the furcation entrance.\n  * Intact tooth structure without root fractures or furcation caries.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases (e.g., uncontrolled diabetes, hypertension, cardiovascular disease, severe osteoporosis).\n* Pregnant or lactating women.\n* Current smokers or individuals who quit smoking less than 6 months prior to enrollment.\n* Use of antibiotics, anti-inflammatory agents, or medications affecting bone metabolism (e.g., bisphosphonates, high-dose corticosteroids, anti-resorptive drugs) within the past 3 months.\n* Previous periodontal surgery at the evaluation site within the past 6 months.\n* Target teeth presenting with:\n\n  * Miller Grade II or Grade III tooth mobility.\n  * Severe bone destruction extending to the root apex.\n  * Metallic restorations (metal crowns, amalgam fillings, or large metallic posts) causing significant scatter\u002Fartifacts on CBCT scans.\n  * Fused roots or abnormal root anatomy.","ALL","18 Years",{"count":19,"type":20},98,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study consists of two components evaluating furcation involvement in mandibular molars among Stage III or Stage IV periodontitis patients. Component 1 is a cross-sectional study evaluating the prevalence and morphological characteristics of Hamp Class II furcation defects during initial screening. Component 2 is a randomized controlled clinical trial in 30 selected patients comparing the diagnostic accuracy of Cone Beam Computed Tomography (CBCT) against direct intra-operative clinical measurements, as well as evaluating the clinical and radiographic outcomes of regenerative periodontal surgery using Acellular Dermal Matrix (ADM) + Enamel Matrix Derivative (EMD) + Xenograft versus Autogenous Connective Tissue Graft (CTG) + EMD + Xenograft.",[26,27,28],"Periodontitis","Periodontitis (Stage 3)","Furcation Defects",[30,31,32,33,34],"Periodontal Regeneration","Connective Tissue Graft","Enamel Matrix Derivative","Acellular Dermal Matrix","Cone-Beam Computed Tomography","RECRUITING","2026-08-14",{"date":38,"type":39},"2026-08-18","ACTUAL",{"date":41,"type":39},"2026-05-02",{"date":43,"type":20},"2028-05",{"name":45,"class":46},"University of Medicine and Pharmacy at Ho Chi Minh City","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100651011","minimally-invasive-non-surgical-periodontal-treatment-100651011","NCT07755644","Minimally Invasive Non-Surgical Periodontal Treatment","The Clinical Effects of Minimally Invasive NonSurgical Therapy (MINST) as an Alternative of Conventional NonSurgical Periodontal Therapy for Stage III Grade C Periodontitis in Molar Teeth- A 6-month Pilot Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 to 35 years.\n* Diagnosed with Stage III or Stage IV periodontitis.\n* Systemically healthy.\n* Presence of at least two bilateral molar teeth with probing pocket depth (PPD) ≥5 mm and bleeding on probing (BOP).\n* At least 20 remaining teeth.\n* Radiographic evidence of periodontal bone loss.\n* Non-smokers and non-users of tobacco or alcohol.\n* Not pregnant or breastfeeding.\n* Not receiving medications known to affect periodontal healing.\n* Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria.\n* Pregnancy or breastfeeding.\n* Presence of systemic diseases or medical conditions affecting periodontal status or healing.\n* Current use of medications that may influence periodontal healing.\n* Current smokers or users of tobacco or alcohol.\n* Individuals unwilling or unable to provide informed consent.","35 Years",{"count":57,"type":20},23,[23],"This single-center, split-mouth, randomized controlled clinical trial aims to evaluate the clinical effectiveness of Minimally Invasive Non-Surgical Therapy (MINST) as an adjunct to conventional non-surgical periodontal therapy in patients with Stage III\u002FIV periodontitis. Twenty-three systemically healthy adults presenting with bilateral molar teeth exhibiting periodontal pockets ≥5 mm with bleeding on probing will be enrolled. In each participant, molar teeth will be randomly allocated to receive either conventional subgingival scaling and root planing (SRP) using ultrasonic instruments alone (control) or conventional SRP followed by MINST using Mini-Five Gracey curettes under magnification loupes (test). Clinical periodontal parameters, including Plaque Index (PI), Gingival Index (GI), Bleeding on Probing (BOP), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), will be evaluated at baseline, 3 months, and 6 months after treatment. The study will investigate whether MINST provides superior clinical outcomes compared with conventional non-surgical periodontal therapy.",[26,27],[26,62,63,64,65,66,67],"Stage III Periodontitis","Stage IV Periodontitis","Minimally Invasive Non-Surgical Therapy","MINST","Scaling and Root Planing","Root Debridement","NOT_YET_RECRUITING","2026-08-05",{"date":71,"type":39},"2026-08-10",{"date":73,"type":20},"2026-08-01",{"date":75,"type":20},"2027-01",{"name":77,"class":46},"Ataturk University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100644677","omega-3-plus-low-dose-aspirin-in-smokers-with-stage-iii-periodontitis-100644677","NCT07673185","Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis","Clinical and Biochemical Evaluation of the Effect of Omega-3 Fatty Acids Plus Low-Dose Aspirin as an Adjunct to Non-Surgical Periodontal Therapy in Smoker Patients With Stage III Periodontitis: A Randomized Double-Blind Placebo-Controlled Clinical Trial","OASP","Inclusion Criteria:\n\n* \\- Male or female smokers aged 30 to 50 years.\n* Diagnosed with Stage III periodontitis according to the 2017 World Workshop classification.\n* Probing pocket depth (PPD) ≥ 5 mm.\n* Clinical attachment loss (CAL) ≥ 5 mm.\n* Presence of at least 20 natural teeth.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* \\- Systemic diseases affecting periodontal health.\n* Pregnancy or lactation.\n* Periodontal treatment within the previous 6 months.\n* Use of antibiotics or anti-inflammatory drugs within the previous 6 months.\n* Allergy or hypersensitivity to omega-3 fatty acids or aspirin.\n* Long-term anticoagulant therapy.\n* History of gastric ulcer or bleeding disorders.\n* Participation in another clinical trial within the previous 3 month","30 Years","50 Years",{"count":89,"type":20},40,[23],"This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment",[93,27,94],"Periodontal Disease","Smoking Behaviors",[96,97,98],"omega 3","smoker","stage 3","2026-07-06",{"date":101,"type":39},"2026-07-08",{"date":103,"type":39},"2025-01-15",{"date":105,"type":20},"2026-10-30",{"name":107,"class":46},"Al-Azhar University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":47},"100645188","influence-of-re-evaluation-timing-after-phase-i-periodontal-therapy-on-clinical-and-periodontal-outcomes-100645188","NCT07678125","Influence of Re-evaluation Timing After Phase I Periodontal Therapy on Clinical and Periodontal Outcomes.","Influence of Re-evaluation Timing After Phase I Periodontal Therapy on Clinical and Periodontal Outcomes. A Split-mouth Study","Inclusion Criteria:\n\n* Patients above 18 yrs\n* Patients that are systemically healthy\n* Patients diagnosed as Stage III or Stage IV Periodontitis\n* Patients willing to participate in the study and provide informed consent.\n* Patients with no recent history of periodontal therapy\n* Presence of ≥20 natural teeth\n\nExclusion criteria:\n\n* Patients with a history of medical conditions or diseases that may affect healing or periodontal tissues.\n* Patients who are pregnant\n* Patients on Drugs\u002Fmedication that may affect the periodontal tissue\n* Smokers or tobacco users\n* Patients that cannot complete the 12-week follow-up period",true,"21 Years","70 Years",{"count":119,"type":20},24,[23],"Periodontal disease remains a highly prevalent chronic inflammatory condition affecting the supporting structures of the teeth and is a leading cause of tooth loss worldwide. Contemporary periodontal therapy is structured into sequential phases, with non-surgical periodontal therapy (NSPT) forming the cornerstone of initial management. Following this phase, re-evaluation of periodontal status is critical to determine treatment outcomes and guide further intervention, including surgical therapy if required (1,2).\n\nRe-evaluation phase serves multiple purposes: it allows assessment of tissue response to therapy, measurement of reductions in probing pocket depth (PPD), gains in clinical attachment level (CAL), and evaluation of patient compliance with oral hygiene practices. It also aids in identifying residual pockets or persistent inflammation that may necessitate additional treatment (1,3). Despite its clinical importance, the optimal timing of re-evaluation remains inconsistently defined in the literature (1). Generally, current literature utilizes a timing frame from 1-3 months; up to 9 months (3,4). Current clinical guidelines, including those from the European Federation of Periodontology (EFP), generally recommend assessing whether the end points have been achieved; no periodontal pockets ≥ 5mm with bleeding on probing and no pocket ≥ 6mm (5).\n\nEmerging evidence suggests that certain clinical improvements, particularly reductions in inflammation and bleeding on probing (BOP), may occur as early as 4 weeks following therapy, raising questions about whether earlier re-evaluation could be clinically beneficial (2,3). Early reassessment may allow for more timely identification of non-responding sites, enabling prompt intervention and potentially improving overall treatment outcomes. Conversely, other studies indicate that full periodontal healing and maturation of tissues may require longer periods, supporting delayed re-evaluation intervals (1,2,3).\n\nFurthermore, patient-related factors such as systemic health, smoking status, and baseline disease severity may influence healing dynamics and thus the appropriate timing for reassessment (1). The heterogeneity of these factors highlights the potential need for a more individualized approach to re-evaluation rather than a fixed universal timeframe.\n\nDespite these considerations, there is a notable lack of high-quality comparative studies directly evaluating short-term versus conventional re-evaluation intervals following NSPT. Most available studies focus on treatment outcomes rather than the timing of reassessment itself. This creates a significant gap in the literature, particularly regarding whether earlier re-evaluation could enhance clinical decision-making, improve patient outcomes, or optimize resource utilization in clinical practice.\n\nIn addition, with increasing emphasis on minimally invasive and patient-centered care, there is a growing need to refine periodontal treatment protocols to ensure efficiency without compromising effectiveness. Determining the optimal timing of re-evaluation could contribute to improved treatment planning, reduced disease progression, and enhanced long-term periodontal stability.\n\nTherefore, this study aims to address this gap by investigating the effectiveness and clinical implications of shorter re-evaluation intervals following periodontal therapy, compared to conventional timeframes.",[123,27,124],"Periodontal Diseases","Subgingival Debridement",[126],"periodontal disease","2026-06-25",{"date":129,"type":39},"2026-07-01",{"date":131,"type":20},"2026-06-01",{"date":133,"type":20},"2027-02-15",{"name":135,"class":46},"Gulf Medical University",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":115,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100644469","bone-substitutes-and-nipsa-in-intrabony-periodontal-defects-a-randomized-controlled-trial-100644469","NCT07671963","Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial","Regenerative Therapy of Intrabony Periodontal Defects Using Bone Substitutes and a Minimally Invasive Nonincised Papilla Surgical Approach - A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of Stage III periodontitis\n* At least one intrabony periodontal defect with probing depth \\> 5 mm following completion of non-surgical periodontal therapy\n* Full-mouth plaque score (FMPS) \\\u003C 20%\n* Full-mouth bleeding score (FMBS) \\\u003C 20%\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Systemic medical contraindications to periodontal surgery\n* History of head and neck radiotherapy\n* Poor oral hygiene or lack of motivation\u002Fcompliance\n* Uncontrolled diabetes mellitus\n* Pregnancy or lactation\n* Treatment with antiresorptive medications or other drugs affecting bone remodeling\n* Heavy smoking (\\>20 cigarettes\u002Fday)","80 Years",{"count":145,"type":20},30,[23],"This multicenter randomized controlled clinical trial aims to compare the clinical, radiographic, microbiological and molecular outcomes of two collagenated xenogeneic bone substitutes (GTO® and GenOs®) used in combination with the Non-Incised Papilla Surgical Approach (NIPSA) for the treatment of intrabony periodontal defects. The study will evaluate whether differences exist between the two biomaterials with respect to clinical attachment gain, defect resolution, wound healing and biological markers of regeneration.",[27,149,150],"Minimally Invasive Surgical Procedures","Bone Substitutes",[152,153,154,155],"periodontitis","regenerative treatment","NIPSA","bone substitutes","2026-06-22",{"date":158,"type":39},"2026-06-26",{"date":129,"type":20},{"date":161,"type":20},"2027-03-01",{"name":163,"class":46},"University of Belgrade",2,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":188},"100586378","a-clinical-trial-comparing-2xday-for-30-minutes-use-of-the-emanate-perio-pods-post-srp-to-a-control-group-post-srp-100586378","NCT06914596","A Clinical Trial Comparing 2x\u002FDay for 30-minutes Use of the Emanate Perio PODS Post-SRP to a Control Group Post-SRP.","Randomized Controlled Clinical Trial To Assess The Safety And Effectiveness Of A Periodontal Hydrogel Wound Dressing (Emanate Perio PODS) On Wound Healing Post-Scaling And Root Planing","Inclusion Criteria:\n\nSubjects must meet all the following criteria to be entered into the study:\n\n1. Subjects will have read, understood, and signed an institutional review board (IRB) approved Informed Consent Form (ICF).\n2. Subjects 30 to 75 years of age.\n3. Generalized Stage III periodontitis with at least 8 teeth having interproximal clinical attachment level of ≥3 mm and a probing pocket depth of ≥5 mm and ≤7mm, distributed between the mandible and the maxilla, with at least 2 qualifying interproximal sites in each arch. Localized and not more than 6 sites with a PD of 8 mm is acceptable as long as the tooth with 8 mm pocket depth is not clinically diagnosed as hopeless tooth with suppuration or mobility Grade 3 or greater.5-7\n4. Subjects have a minimum of 24 natural teeth with a minimum of 2 natural teeth per quadrant excluding third molars.\n5. All supragingival accretions can be removed from below the height of contour of the tooth crown to allow for a comprehensive periodontal evaluation and accurate intraoral digital scan of both arches at screening.\n6. Subjects agree to refrain from use of oral rinses or dentifrice with known antibacterial properties (e.g., Peridex®, Listerine®, Colgate Total®, Crest Pro-Health®, etc.).\n7. Subjects agree to refrain from use of electric flossers or irrigation devices for the duration of the study.\n8. Subjects can provide self-care (oral hygiene) without disabilities requiring assistance with daily oral hygiene measures.\n9. Subjects are able and willing to follow study procedures and instructions.\n\nExclusion Criteria:\n\nSubjects who meet the above inclusion criteria will be eligible for the study, unless they present with any of the following:\n\n1. Periodontal surgery, implant placement or SRP within 12 months prior to screening or a cleaning\u002Fprophylaxis three months prior to screening.\n2. Presence of fixed or removable (e.g. Invisalign) orthodontic appliances.\n3. Subject with an underlying medical condition which requires antibiotic prophylaxis prior to dental treatment.\n4. Subjects with vesiculobullous processes or other similar chronic oral lesions \u002F conditions resulting in gingival irritation, discomfort\u002Fpain, or erosions.\n5. Subjects with soft or hard tissue tumor(s) of oral cavity.\n6. Use of any smoked substances such as tobacco \u002F cannabis including cigarettes, vape, cigars, or use of smokeless tobacco 30 days prior to screening and throughout the study.\n7. Uncontrolled medical conditions (e.g., diabetes mellitus, hypertension, cancer).\n8. Subjects who are lactating or pregnant or planning to become pregnant through their projected study duration.\n9. Subjects taking medications known to affect gingival conditions. (e.g., hyperplasia).\n10. Regular, prolonged use of oral antimicrobial rinses 30 days prior to screening or continued anticipated use through their projected study duration.\n11. Use of systemic antibiotics 30 days prior to screening or anticipated during the trial period.\n12. Subjects taking corticosteroids on a regular basis one week prior to baseline examination and throughout the duration of the study, including oral inhalers.\n13. Subjects taking non-steroidal anti-inflammatory (NSAIDS) or other pain medication on a daily basis for more than 3 consecutive days beginning one week prior to the baseline examination and throughout the duration of the study. Subjects are allowed to take 81 mg\u002Fday aspirin and may use oral pain medication if needed in the first 48- hours post-SRP period.\n14. Subjects taking anticoagulant medications such as warfarin or Plavix or Eliquis.\n15. Subjects participating in other clinical studies involving therapeutic intervention (either medical or dental) within 30 days of Screening.\n16. Subjects that are known to be hypersensitive to chlorhexidine gluconate, glycerin, polyvinyl alcohol or ethylene vinyl acetate.\n17. Subjects, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.","75 Years",{"count":174,"type":20},72,[23],"The goal of this clinical trial is to compare safety and to see if individuals with generalized stage III periodontitis that are given a periodontal hydrogel dressing on a wound healing after plaque and tartar have been removed from teeth have greater healing than individuals who are given no treatment after.",[27],"2026-06-19",{"date":180,"type":39},"2026-06-24",{"date":182,"type":39},"2026-02-19",{"date":184,"type":20},"2027-01-30",{"name":186,"class":187},"McGuire Institute","INDUSTRY",9,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":115,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":47},"100635203","application-of-a-fasting-mimicking-diet-in-obese-patients-with-periodontitis-stage-iii-iv-100635203","NCT07549633","Application of a Fasting-mimicking Diet in Obese Patients With Periodontitis Stage III-IV","Inclusion Criteria:\n\n* 18-70-year-old patients,\n* Severe Periodontitis (Stages III-IV),\n* Systemically healthy,\n* Overweight (body mass index - BMI \\> 30 kg\u002Fm2),\n* Absence of hopeless teeth, acute dental conditions, endo-perio lesions and necrotising periodontal diseases,\n* Minimum of 20 teeth present.\n\nExclusion Criteria:\n\n* Current smokers,\n* Pregnant women,\n* Patients drinking more than 20 units of alcohol weekly,\n* Taking medications including systemic anti-inflammatory medication within 3 months of the study,\n* Periodontal treatment and\u002For systemic antibiotics intake within preceding 3 months\n* Denture wearer\u002Fpresence of dental implants,\n* Significant food allergies and\u002For special dietary requirements which would make the subject unable to consume the food provided.",{"count":89,"type":20},[23],"This study will evaluate whether a fasting-mimicking diet (FMD) can improve the systemic and periodontal response to non-surgical periodontal treatment in obese adults with severe periodontitis. Periodontitis is a serious inflammatory disease that damages the tissues supporting the teeth and may also contribute to inflammation elsewhere in the body. Obesity is also associated with increased systemic inflammation, which may worsen periodontal disease and affect treatment outcomes.\n\nIn this pilot randomized cross-over clinical trial, eligible participants will receive full-mouth non-surgical periodontal therapy and will be assigned either to an FMD group or to a control group continuing their usual diet. The FMD will be administered in three 5-day cycles around the periodontal treatment period. After a wash-out period, the groups will switch interventions.\n\nThe study will assess whether FMD can reduce systemic inflammation, measured primarily by serum C-reactive protein (CRP), and improve periodontal healing after treatment. Additional outcomes include clinical periodontal measurements, inflammatory markers in gingival crevicular fluid, and changes in oral and gut microbiota. Findings from this study will help determine the feasibility of this dietary approach and provide preliminary data for a larger clinical trial.",[27,199],"Periodontitis Stage IV",[201,152,202,203],"non surgical treatment","fasting mimicking diet","systemic response","2026-04-17",{"date":206,"type":39},"2026-04-24",{"date":131,"type":20},{"date":209,"type":20},"2027-12-01",{"name":211,"class":46},"Akdeniz University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100629249","periodontal-dressings-in-non-surgical-therapy-100629249","NCT07472218","Periodontal Dressings in Non-Surgical Therapy","Comparison of the Effectiveness of Two Different Periodontal Wound Dressings in Non-Surgical Periodontal Therapy","Inclusion Criteria:\n\n1. Systemically healthy volunteers aged 18-45 years.\n2. Diagnosis of Periodontitis (Stage 3, Grade A).\n3. Presence of at least 20 permanent teeth.\n4. Capacity to understand the study protocol and provide informed consent.\n\nExclusion Criteria:\n\n1. Systemic diseases (e.g., Diabetes, Chronic Renal Failure, Cancer, Connective Tissue Disorders).\n2. Pregnancy or breastfeeding.\n3. Smoking (\\>10 cigarettes\u002Fday).\n4. Antibiotic use within the last 3 months or periodontal treatment within the last year.\n5. Presence of orthodontic appliances, removable prostheses, or extensive interproximal caries.","60 Years",{"count":221,"type":20},25,[23],"This study aims to evaluate and compare the efficacy of two different eugenol-free periodontal dressing materials-Ora-Aid (a hydrophilic polymer) and Coe-Pak (a zinc oxide-based paste)-following non-surgical periodontal treatment (scaling and root planing, SRP) in patients with Stage 3, Grade A periodontitis. The study utilizes a split-mouth design to analyze clinical periodontal parameters, patient comfort, and microbiological changes over a 3-month period.",[26,27,225],"Periodontal Pocket",[152,227,228,229,230,231],"Non-surgical periodontal therapy","Periodontal dressing","Ora-Aid","Coe-Pak","total bacterial load","2026-03-13",{"date":234,"type":39},"2026-03-16",{"date":236,"type":20},"2026-04-01",{"date":238,"type":20},"2026-10-01",{"name":240,"class":46},"Saglik Bilimleri Universitesi",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":115,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":47},"100627036","microbiological-and-clinical-effects-of-pre--and-probiotics-in-non-surgical-periodontal-therapy-100627036","NCT07443410","Microbiological and Clinical Effects of Pre- and Probiotics in Non-Surgical Periodontal Therapy","PROPARO","Inclusion Criteria:\n\n* Age ≥ 18 years\n\n  * Stage III or IV periodontitis (localized or generalized)\n  * Ability to provide informed consent\n  * Written informed consent including data protection consent\n\nExclusion Criteria:\n\n* • Pregnancy or breastfeeding\n\n  * Conditions\u002Fmedications likely to substantially confound the oral microbiome or periodontal healing (e.g., uncontrolled diabetes mellitus, systemic immunosuppression, chronic steroid use)\n  * Antibiotic use within the last 3 months\n  * Use of oral pre-\u002Fprobiotic supplements within the last 3 months\n  * Recent subgingival instrumentation within the last 6 months\n  * Need for obligatory adjunctive systemic antibiotic prophylaxis\u002Ftherapy for NSPT\n  * Severe active systemic infection or other conditions judged by investigators to pose undue risk\n  * Regular use of antiseptic mouthrinses during the study period (unless medically required)\n  * Strict diets likely to substantially alter baseline microbiome trajectories (e.g., ketogenic, strict vegan) per protocol definition\n  * Chronic bowel diseases (for systemic confounding considerations)",{"count":249,"type":20},60,[23],"Periodontitis is a prevalent chronic inflammatory disease driven by a dysbiotic oral biofilm and a dysregulated host immune response. Standard non-surgical periodontal therapy (NSPT) is primarily mechanical and, in selected cases, may be accompanied by antiseptics or systemic antibiotics. Targeted modulation of the oral microbiome (\"microbiome engineering\") is currently not part of routine periodontal care due to limited high-quality evidence.\n\nPROPARO is a single-center, randomized, controlled pilot study designed to assess whether adjunctive oral supplementation with a probiotic containing Limosilactobacillus reuteri (commercial dietary supplement lozenge) alone or combined with vitamin B12 (commercial dietary supplement drops) is associated with changes in supragingival and subgingival oral microbiome composition during guideline-concordant NSPT compared with standard care alone. Participants with Stage III or IV periodontitis will be randomized 1:1:1 to: (1) NSPT\u002FSPT without supplementation (control), (2) NSPT\u002FSPT plus probiotic lozenges for 3 months, or (3) NSPT\u002FSPT plus probiotic lozenges and vitamin B12 drops for 3 months.\n\nThe primary outcome is change in oral microbiome composition and structure (supragingival and subgingival), assessed using 16S rDNA-based profiling and metagenomic sequencing approaches. Secondary outcomes include clinical periodontal parameters (e.g., probing depth, clinical attachment level, bleeding on probing), oral hygiene\u002Fgingival indices, dental status, and participant-level ecological covariates (diet quality, perceived stress, physical activity). Sampling and assessments are aligned with routine care time points from baseline through supportive periodontal therapy follow-up (up to 12 months). This pilot trial aims to generate feasibility and effect-size estimates to inform future confirmatory studies and potential translation into guideline-based periodontal care.",[253,27,199],"Periodontitis, Adult",[26,255,256,257,258],"Non-surgical periodontal treatment","Probiotics","Prebiotics","Oral Microbiome","2026-02-24",{"date":261,"type":39},"2026-03-02",{"date":263,"type":39},"2024-10-25",{"date":265,"type":20},"2026-10",{"name":267,"class":46},"University Hospital Heidelberg",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":280,"conditions":281,"keywords":288,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":47},"100615542","phase-2-3-month-clinical-trial-of-liquid-s-prf-in-periodontal-debridement-for-periodontitis-stages-ii-iv-100615542","NCT07293962","3-Month Clinical Trial of Liquid S-PRF in Periodontal Debridement for Periodontitis Stages II-IV","Liquid S-Platelet Rich Fibrin as a Potential Adjunct in Conservative Closed Periodontal Debridement for Periodontitis Stages II-IV: A Randomized, Split-mouth, 3-month Clinical Trial","Inclusion Criteria:\n\n* Have at least 20 teeth,\n* American Society of Anesthesiology class I or II\n* Periodontitis stages II-IV\n* Bilateral sites of deep periodontal pockets ≥5 mm\n\nExclusion Criteria:\n\n* Limited mouth opening or symptomatic temporomandibular joint disorder\n* Inability to tolerate extended long periodontal treatment and\u002For hyperactive gag reflex\n* Current or former smoker or vape user\n* Pregnant and\u002For breastfeeding\n* Having diabetes mellitus type I or II\n* Having bleeding disorder or is on anticoagulants\n* Underwent periodontal treatment and\u002For surgery in past 6 months prior\n* Undergoing orthodontic therapy, or completed in past 3 months prior\n* On or had anti-inflammatory drug(s) in past 3 months prior\n* On or had antibiotic(s) in past 3 months prior\n* Having autoimmune disorder\n* On or had immunosuppressant drug(s) in past 3 months prior\n* Undergoing or underwent radio- and\u002For chemo-therapy","65 Years",{"count":277,"type":20},14,[279],"PHASE2","What is the purpose of this study? This study is to investigate the effect of a processed blood product in healing after treatment for gum disease. In addition to scaling \\& root debridement (deep cleaning) that is the standard treatment for periodontitis, this study will test the effectiveness of patient's processed blood in improving healing of diseased gums.\n\nWhat are the procedures to be followed? First, all patients will undergo dental check-up and X-ray imaging for suitability as a participant for the project. For participants who are eligible and included into study, upper \\& lower jaws models will be made, and each will be given oral care kit \\& instructions. The next appointment will be given for scaling \\& root debridement with local numbing agent in one day. Towards the end of the treatment, a small amount (20 mℓ) of blood will be collected and spun to produce liquid platelet-rich fibrin that is then used to flush the treated gum pockets in half of the mouth. For the treated gum pockets in the opposite half of the mouth, sterile salt water (saline) will be used instead for comparison. Then, follow-up appointments are at monthly intervals until 3 months.\n\nWho should enter the study? Symptoms of gum disease include bleeding and\u002For receding gums, tooth\u002Fteeth appearing longer or feeling shaky\u002Floose\u002Fweak, formation of large amount of calculus and\u002For black\u002Fempty space between teeth, frequent\u002Frecurrent gum swelling\u002Fpus, and\u002For bad breath.",[282,283,27,26,284,285,286,253,287],"Periodontitis Stage II","Periodontitis Stage III","Periodontitis Chronic Localized Slight","Periodontitis Chronic Generalized Moderate","Periodontitis Chronic Generalized Severe","Periodontitis, Chronic",[289,152,290,291,292,293,294,295,296,297,298,299],"periodontal treatment","platelet concentrates","platelet-rich fibrin","nonsurgical","clinical trial","periodontal","nonsurgical periodontal debridement","dental scaling","periodontal diseases","periodontal debridement","nonsurgical periodontal treatment","2025-12-07",{"date":302,"type":39},"2025-12-19",{"date":304,"type":39},"2024-04-01",{"date":306,"type":20},"2026-03",{"name":308,"class":46},"Mahsa University",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":115,"sex":16,"minAge":4,"maxAge":117,"enrollmentInfo":315,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":318,"conditions":319,"keywords":320,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":47},"100599882","phase-3-evaluation-of-the-periodontal-parameters-following-non-surgical-periodontal-therapy-with-and-without-adjunctive-use-of-injectable-platelet-rich-fibrin-a-randomized-controlled-clinical-trial-100599882","NCT07090265","Evaluation of The Periodontal Parameters Following Non-Surgical Periodontal Therapy With and Without Adjunctive Use of Injectable Platelet Rich Fibrin: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nMedically free, Non-smokers, Stage III Periodontitis Patients, Probing depth \\\u003C5mm\n\nExclusion Criteria:\n\n* Systemic disease, Smoking, Pregnancy, History of Chemotherapy, Radiotherapy",{"count":145,"type":20},[317],"PHASE3","This randomized controlled clinical trial aims to evaluate the effectiveness of non-surgical periodontal therapy (NSPT) with and without the adjunctive use of injectable platelet-rich fibrin (I-PRF) in patients with chronic periodontitis. The primary objective is to assess changes in key periodontal parameters including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque index (PI) over a defined follow-up period. Participants will be randomly assigned to two groups: one receiving standard NSPT alone and the other receiving NSPT combined with subgingival application of I-PRF. The study seeks to determine whether the adjunctive use of I-PRF can enhance periodontal healing and improve clinical outcomes compared to conventional therapy alone.",[27],[26,321,322,323],"Injectable Platelet Rich Fibrib","Non-surgical Periodontal Therapy","Adjunctive Therapy","2025-07-21",{"date":326,"type":39},"2025-07-29",{"date":328,"type":20},"2025-07",{"date":330,"type":20},"2025-10",{"name":332,"class":46},"Cairo University"]